• Corpus ID: 15223245

Experimental Researches of Cutaneous Melanoma Immunotherapy by Antitumor Cell-Whole GM-CSF-Producing Vaccines

  title={Experimental Researches of Cutaneous Melanoma Immunotherapy by Antitumor Cell-Whole GM-CSF-Producing Vaccines},
  author={I. V. Manina and N. M. Peretolchina and N. S. Saprikina and Aleksey Kozlov and I. N. Mikhaylova and A.Yu.Barishnikov},
  journal={arXiv: Other Quantitative Biology},
Various approaches to increase efficiency of antitumor therapy by a combination of vaccinotherapy, chemotherapy and surgical excision of primary tumor nodes, and also the comparative analyses of therapeutic and preventive application of antitumoral vaccines were carried out in melanoma experimental model. It was postulated that preventive vaccination is able to prevent tumor incidence by 70 %. The combination of vaccinotherapy and surgical treatment of melanoma increases antimetastatic activity… 

Figures and Tables from this paper



GM-CSF-based cellular vaccines: a review of the clinical experience.

Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy.

This combination chemoimmunotherapy caused complete regression of advanced primary melanomas in the skin and metastases in the lung with minimal autoimmune side effects and provides a scientific rationale to evaluate similar strategies which unleash the power of innate and adaptive immune defense in future clinical trials.

GM-CSF-secreting melanoma vaccines

Vaccination with irradiated melanoma cells engineered to secrete GM-CSF enhances host responses through improved tumor antigen presentation by recruited dendritic cells and macrophages, and granulocyte–macrophage colony stimulating factor is identified as the most potent molecule for augmenting tumor immunity following gene transfer into melanoma Cells.

B16 as a Mouse Model for Human Melanoma

This unit details protocols for in vivo models of subcutaneous growth and pulmonary metastases of B16 melanoma and the induction and use of gp100‐specific therapeutic cytotoxic T lymphocytes (CTL) are discussed.

Strategies to Enhance the Therapeutic Activity of Cancer Vaccines: Using Melanoma as a Model

  • N. Berinstein
  • Biology, Medicine
    Annals of the New York Academy of Sciences
  • 2009
Sanofi Pasteur designed a clinical trial in patients with advanced or metastatic melanoma that is intended to both induce tumor‐specific T‐cell responses and modulate or reverse some of the immune suppression pathways that the melanoma has induced.

Systemic therapy for cutaneous melanoma.

GM-CSF Gene-Modifed Cancer Cell Immunotherapies: Of Mice and Men

GVAX cancer immunotherapies are composed of whole tumor cells genetically modified to secrete the immune stimulatory cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF), and then

Внутрикожная клеточная реакция на фоне вакцинотерапии меланомы кожи

Patients with allogenic genemodified tumor cell based vaccine showed well-defined morphological changes of the skin in comparison with patients who received autologous dendritic cell vaccine primed with oncolysate in vitro.